Compositions containing HC-HA/PTX3 complexes and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/525
A61L-027/34
A61L-031/16
A61L-029/08
A61L-029/16
A61L-031/10
A61K-038/19
A61L-027/54
C07K-001/36
A61K-047/48
C07K-014/47
C07K-019/00
C07K-014/81
A61K-038/00
출원번호
US-0414047
(2013-07-10)
등록번호
US-10040821
(2018-08-07)
국제출원번호
PCT/US2013/049983
(2013-07-10)
국제공개번호
WO2014/011813
(2014-01-16)
발명자
/ 주소
Tseng, Scheffer
He, Hua
Tighe, Sean
Zhang, Suzhen
Zhu, Ying-Tieng
출원인 / 주소
TISSUETECH, INC.
대리인 / 주소
Wilson, Sonsini, Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
56
초록▼
Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and
Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.
대표청구항▼
1. A purified, reconstituted HC-HA/PTX3 (rcHC-HA/PTX3) complex produced in vitro by a method comprising (a) contacting high molecular weight hyaluronan (HMW HA) with (i) pentraxin 3 (PTX3) protein, (ii) inter-α-inhibitor (IαI) protein comprising heavy chain 1 (HC1) and heavy chain 2 (HC2) and (iii)
1. A purified, reconstituted HC-HA/PTX3 (rcHC-HA/PTX3) complex produced in vitro by a method comprising (a) contacting high molecular weight hyaluronan (HMW HA) with (i) pentraxin 3 (PTX3) protein, (ii) inter-α-inhibitor (IαI) protein comprising heavy chain 1 (HC1) and heavy chain 2 (HC2) and (iii) tumor necrosis factor α-stimulated gene 6 (TSG-6) to form an rcHC-HA/PTX3 complex comprising HMW HA, HC1, HC2, and PTX3; and (b) purifying the rcHC-HA/PTX3 complex from unwanted components. 2. A reconstituted HC-HA/PTX3/SLRP complex comprising high molecular weight hyaluronan (HMW-HA); pentraxin-3 (PTX3) protein; heavy chain 1 (HC1) and heavy chain 2 (HC2) of inter-α-inhibitor (IαI); and a small leucine rich proteoglycan (SLRP). 3. A method of preventing or reversing scar formation or fibrosis in a tissue, comprising administering to a subject in need thereof an effective amount of the rcHC-HA/PTX3 complex of claim 1. 4. A method of preventing or reducing inflammation in a subject in need thereof, comprising administering to the subject an effective amount of the rcHC-HA/PTX3 complex of claim 1. 5. The method of claim 4, wherein the inflammation is associated with an autoimmune disorder, an allergy, a leukocyte defect, an infection, graft versus host disease, tissue transplant rejection, or combinations thereof. 6. A method of treating a skin wound or ulcer in a subject in need thereof, comprising administering to the subject an effective amount of the rcHC-HA/PTX3 complex of claim 1. 7. A method of promoting or inducing bone formation in a subject in need thereof, comprising administering to the subject an effective amount of the rcHC-HA/PTX3 complex of claim 1, wherein the subject has arthritis, osteoporosis, alveolar bone degradation, or Paget's disease. 8. A method of preventing or reducing unwanted angiogenesis in a subject in need thereof, comprising administering to the subject an effective amount of the rcHC-HA/PTX3 complex of claim 1. 9. A method of inhibiting or preventing transplant rejection in a transplant recipient, comprising administering to the subject an effective amount of an rcHC-HA/PTX3 complex of claim 1. 10. A method of inducing stem cell expansion, comprising contacting a stem cell in vitro with an effective amount of the rcHC-HA/PTX3 complex of claim 1 or the reconstituted HC-HA/PTX3/SLRP complex of claim 2. 11. A method of providing a cell therapy to a subject in need thereof, comprising administering to the subject an effective amount of the rcHC-HA/PTX3 complex of claim 1. 12. The method of claim 11, wherein the therapeutic cell is selected from the group consisting of a stem cell, an adult stem cell, an induced pluripotent stem cell, a mesenchymal stem cell, a limbal epithelial progenitor cell, a limbal stromal niche cell, an umbilical cord stem cell, an amniotic membrane stem cell, an adipose stem cell, a differentiated cell, an insulin producing cell, and an islet cell. 13. A medical device, comprising a substrate coated with the rcHC-HA/PTX3 complex of claim 1. 14. The rcHC-HA/PTX3 complex of claim 1, wherein the PTX3 protein is a native PTX3 protein or a recombinant PTX3 protein, and the TSG-6 protein is a native TSG-6 protein or a recombinant TSG-6 protein. 15. The rcHC-HA/PTX3 complex of claim 1, wherein the IαI protein further comprises a bikunin, a chondroitin sulfate chain, or any combinations thereof. 16. The rcHC-HA/PTX3 complex of claim 1, wherein the IαI protein is isolated from blood, serum, plasma, amniotic membrane, chorionic membrane, amniotic fluid, or a combination thereof. 17. The rcHC-HA/PTX3 complex of claim 14, wherein the IαI protein, the native TSG-6 protein, and/or the native PTX3 protein is produced by an amniotic membrane cell. 18. The rcHC-HA/PTX3 complex of claim 1, wherein the PTX3 is a homomultimer. 19. The rcHC-HA/PTX3 complex of claim 1, wherein the average molecular weight of the HMW HA is 3,000 kDa or greater. 20. The rcHC-HA/PTX3 complex of claim 1, wherein the contacting is at a molar ratio of IαI:TSG-6 of 3:1 or greater. 21. The rcHC-HA/PTX3 complex of claim 1, further comprising a TSG-6. 22. The rcHC-HA/PTX3 complex of claim 1, wherein the complex consists of HMW HA, HC1, HC2, and PTX3. 23. The rcHC-HA/PTX3 complex of claim 1, wherein the complex consists of HMW HA, HC1, HC2, PTX3, and TSG-6. 24. The rcHC-HA/PTX3 complex of claim 1, wherein the complex is anti-inflammatory.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (56)
Lee Ping I. (Berwyn PA), Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentrati.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Wisniewski, Hans-Georg; Cowman, Mary K.; Band, Philip, Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same.
Schlameus Herman W. (San Antonio TX) Fox William C. (San Antonio TX) Mangold Donald J. (San Antonio TX) Triplett Robert G. (Dallas TX) Holt George R. (San Antonio TX) Aufdemorte Thomas B. (Lakeway TX, Composition and method of promoting hard tissue healing.
Kris P. Antonsen ; Rajiv Nayar ; Wei Wang ; Margaret Caudle ; Michael A. Shearer ; Neville M. Concessio, Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations.
Dansereau Richard J. (Sherburne NY) Mosher Russell Y. (Norwich NY) Axelrod Douglas W. (Norwich NY) Sietsema William K. (Norwich NY), Dosage forms of risedronate.
Brown Karen K. (Kansas City MO) Greene Nathan D. (Leawood KS) Trump Sandy L. (DeSoto KS) Bryant Sharon A. (Shawnee KS), Low viscosity high molecular weight filter sterilizable hyaluronic acid.
Chandrasekaran Santosh Kumar (Palo Alto CA) Urquhart John (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Method and therapeutic system for providing chemotherapy transdermally.
Radebaugh Galen W. (Maple Glen PA) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release acetaminophen formulation and process.
Kelm Gary Robert (Cincinnati OH) Manring Gary Lee (Hamilton OH), Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Phillips Richard E. (San Marcos TX) Moore Mark A. (Austin TX) Russell Ruth L. (Long Beach CA) Cheung David (Arcadia CA), Sterilization of tissue implants using iodine.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Davis Roosevelt (27 Lullwater Estate Rd. Atlanta GA 30307) Primo-Davis Susan A. (27 Lullwater Estate Rd. Atlanta GA 30307), Transdermal therapeutic formulation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.